WASHINGTON, April 29, 2026 — The Microbiome Therapeutics Innovation Group (MTIG) today announced the addition of Nestlé Health Science to its coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products to address unmet medical needs, improve clinical outcomes, and reduce health care costs.

Nestlé Health Science, a globally managed business unit of Nestlé, is a leader in the science of nutrition. Nestlé is committed to redefining the management of health, offering an extensive portfolio of science-based consumer health, medical nutrition, pharmaceutical therapies, and vitamin and supplement brands. Nestlé, in collaboration with Seres Therapeutics, brought VOWST® (fecal microbiota spores, live-brpk) to patients—the first orally approved microbiome therapy for prevention of recurrent Clostridioides difficile infection in adults following antibacterial treatment.

“We are pleased to welcome Nestlé Health Science to our growing coalition of microbiome therapeutics companies. As the stewards of VOWST, the first FDA-approved oral microbiome therapy, Nestlé Health Science brings unparalleled commercial and regulatory expertise to our membership,” commented Johan van Hylckama Vlieg, PhD, CSO & Co-Founder of Freya Biosciences and MTIG Chairman. “We look forward to working alongside the Nestlé team as we pursue tangible policy solutions that expand patient access to life-changing FDA-approved microbiome therapies.”

Luis Briz, President, Professional Health, Nestlé Health Science added, “Joining Microbiome Therapeutics Innovation Group reflects our commitment to responsible, science‑led advancement of microbiome therapeutics. Together with fellow members, we’ll champion clear, pragmatic pathways that help bring safe, effective microbiome medicines to more patients.”

All pharmaceutical and biotechnology companies pursuing regulatory approvals for microbiome therapeutics and microbiome-based products are eligible for consideration of membership in MTIG. If you are interested in learning more about becoming a member of MTIG, please contact us here.
For more information about Nestlé Health Science, visit www.nestlehealthscience.us

About The Microbiome Therapeutics Innovation Group

The Microbiome Therapeutics Innovation Group (MTIG) is a coalition of companies leading the research and development of FDA-approved microbiome therapeutics and microbiome-based products to address unmet medical needs, improve clinical outcomes, and reduce health care costs. The human microbiome is one of the new frontiers of medical innovation that has the potential to benefit patients suffering from numerous diseases afflicting millions of patients and consuming billions of dollars of healthcare resources. MTIG is committed to working with stakeholders who share in our mission and seek tangible policy and regulatory solutions in the emerging microbiome arena. Through a collective voice, the MTIG membership works together to enhance the regulatory, investment, and commercial environment to accelerate microbiome therapeutic product development and enable the field to reach its potential to benefit patients.

Today, MTIG is comprised of ten microbiome therapeutics companies: BiomeSense, Freya Biosciences, Maat Pharma, Nestlé Health Science, Rebiotix, Inc., a Ferring Company, Seres Therapeutics, Siolta Therapeutics, and Vedanta Biosciences. For more information, visit www.microbiometig.org.

About The Conafay Group

The Conafay Group (TCG) is a life-sciences government relations firm based in Washington D.C. that serves as Washington counsel and coalition manager for MTIG. TCG specializes in representing life sciences companies, universities, and other organizations in the biomedical sector before the federal government and associated stakeholders. For more information, visit: www.conafaygroup.com.